Relationship of vascular thrombosis and inflammatory leukocyte infiltration to neointimal growth following porcine coronary artery stent placement

Atherosclerosis

Volumn 124, Issue 2, 1996, Pages 145-155

  Miller, D Douglas ^a   Karim, M Asad ^a   Edwards, William D ^b   Schwartz, Robert S ^b  

^a S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Angioplasty; Coronary artery disease; Fibrin; Leukocytes; Restenosis; Vascular stent

Indexed keywords

FIBRIN;

ANGIOPLASTY; ANIMAL MODEL; ARTICLE; CORONARY ARTERY DISEASE; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; STENT; SWINE;

EID: 0030565006     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05753-X     Document Type: Article

References (47)

1. [1] Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vliestra RE, Holmes DR. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 1990;82:2190-2200.
2. [2] Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vliestra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary injury: results in a porcine model. J Am Coll Cardiol 1992;19:267-274.
3. [3] Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992;20:1284-1293.
4. [4] Chesebro JH, Lam JYT, Badimon L, Fuster V. Restenosis after arterial angioplasty: a hemorrheologic response to injury. Am J Cardiol 1987;60:10B-16B.
5. [5] Kaplan AV, Leung LLK, Leung WH, Grant GW, McDougall F, Fischell TA. Roles of thrombin and platelet membrane glycoprotein IIb/IIIa in platelet subendothelial deposition after angioplasty in an ex vivo whole artery model. Circulation 1991;84:1279-1288.
6. [6] Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991;84:232-243.
7. [7] Buchwald AB, Sandrock D, Unterberg C, Ebbecke M, Nebendahl K, Luders S, Munz DL, Wiegand V. Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. J Am Coll Cardiol 1993;21:249-254.
8. [8] Faxon DP, Sanborn TA, Haudenschild CC, Ryan TJ. Effect of antiplatelet therapy on restenosis after experimental angioplasty. Am J Cardiol 1984;53:72C-76C.
9. [9] Ip JH, Fuster V, Badimon L, Taubman MB, Chesbro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990;15:1667-1687.
10. [10] Nobuyoshi N, Kimura T, Ohisi, Horiuchi H, Nosaka H, Hamasaki N, Yokoi H, Kim K. Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol 1991;17:433-439.
11. [11] Haudenschild CC. Restenosis: basic considerations. In: Topol, EJ (ed). Textbook of Interventional Cardiology, Chapter 17, Section II. Philadelphia, PA: Saunders, 1990.
12. [12] Dinerman JL, Mehta JL. Endothelial, platelet and leukocyte interactions in ischemic heart disease: insights into potential mechanisms and their clinical relevance. J Am Coll Cardiol 1990;16:207-222.
13. [13] Casscells W. Migration of smooth muscle and endothelial cells. Critical events in restenosis. Circulation 1992;86:723-729.
14. [14] Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991;64:5-15.
15. [15] Senior RM, Skogen WF, Griffin GL, Wilner GD. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Invest 1985;77:1014-1019.
16. [16] Beusekom HMM, Van der Giessen WJ, Van Suylen RJ, Bos E, Bosman FT, Serruys PW. History after stenting of human saphenous vein bypass grafts: observations from surgically excised grafts 3 to 320 days after stent placement. J Am Coll Cardiol 1993;21:45-54.
17. [17] Karas SP, Gravinis MB, Santoian EC, Robinson KA, Anderberg KA, King SB III. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol 1992;20:467-474.
18. [18] Topol EJ, Califf RM, Weisman HF et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-886.
19. [19] Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. New Engl J Med 1988;318:1714-1719.
20. [20] Ellis SG, Roubin GS, Wilentz J, Douglas JS, King SB III. Effect of 18 to 24 hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989;117:777-782.
21. [21] Cadroy Y, Maraganore JM, Hanson SR, Harker LA. Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons. Proc Natl Acad Sci USA 1991;88:1177-1181.
22. [22] Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional angioplasty, stenting and directional atherectomy. J Am Coll Cardiol 1993;21:15-25.
23. [23] Serruys PW, Strauss BH, Beatt KJ, Bertrand ME, Puel J, Rickards AF, Meier B, Goy J-J, Vogt P, Kappenberger L, Sigwart U. Angiographic follow-up after placement of a self expanding coronary artery stent. New Engl J Med 1991;324:13-17.
24. [24] Rodgers GP, Minor ST, Robinson K, Comeens D, Woolbert SC, Stephens LC, Guyton JR, Wright K, Roubin GS, Raizner AE. Adjuvant therapy for intracoronary stents. Investigations in atherosclerotic swine. Circulation 1990;82:560-569.
25. [25] Naito M, Hayashi T, Kuzuya M, Funaki C, Asai K, Kuzuya F. Effects of fibrin and fibrinogen on the migration of vascular smooth muscle cells in vitro. Atherosclerosis 1990;83:9-14.
26. [26] Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991;253:1129-1132.
27. [27] Zhong C-H, Hayzer DA, Corson M, Runge MS. Molecular cloning of the rat vascular smooth muscle cell thrombin receptor. Evidence for in vitro regulation by basic fibroblast growth factor. J Biol Chem 1992,267:16975-16979.
28. [28] Harlan JM, Thompson PJ, Ross RR, Bowen-Pope DF. Alpha-thrombin induces release of platelet-derived growth factor like molecules by cultured human endothelial cells. J Cell Biol 1986;103:1129-1133.
29. [29] Miller DD, Craig FE, Dressler FA, Farrar MA, Breland CM, Bach RG, Donohue TJ, Chaitman BR, Aguirre FV. Immunohistochemical characterization of the lymphoid/ mononuclear cell composition of human atherectomy tissue: correlation with interleukin-2 receptor expression. Circulation 1992;86(Suppl I):I-800.
30. [30] Hansson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanisms in atherosclerosis. Arteriosclerosis 1989;9:567-578.
31. [31] Watt SL, Auerbach R. A mitogenic factor for endothelial cells obtained from mouse secondary mixed leukocyte cultures. J Immunol 1986;136:197-202.
32. [32] Colvin RB, Dvorak HJ. Fibrinogen/fibrin on the surface of macrophages: detection, distribution, binding requirements and possible role in macrophage adherence phenomenon. J Exp Med 1975;142:1377-1390.
33. [33] Altieri DC, Mannucci PMM, Capitanio AM. Binding of fibrinogen to human monocytes. J Clin Invest 1986;78:968-976.
34. [34] Tipping PG, Malliaros J, Holdsworth SR. Procoagulant activity expression by macrophages from atheromatous vascular plaques. Atherosclerosis 1989;79:237-243.
35. [35] Hogg N. Human monocytes have prothrombin cleaving activity. Clin Exp Immunol 1983;53:725-730.
36. [36] Hogg, N. Human monocytes are associated with the formation of fibrin. J Exp Med 1983;157:473-485.
37. [37] Bini A, Fenoglio JJ, Mesa-Tejada R, Kudryk B, Kaplan KL. Identification and distribution of fibrinogen, fibrin and fibrin(ogen) degradation products in atherosclerosis. Arteriosclerosis 1989;9:109-121.
38. [38] Gonda SR, Shainoff JR. Absorptive endocytosis of fibrin monomer by macrophages: evidence of a receptor for the amino-terminus of the fibrin alpha-chain. Proc Natl Acad Sci USA 1982;79:4566-4569.
39. [39] Geczy CL, Hopper KE. A mechanism of migration inhibition in delayed hypersensitivity reactions. II. Lymphokines promote procoagulant activity of macrophages in vitro. J Immunol 1981;126:1059-1065.
40. [40] Richardson DL, Pepper DS, Kay AB. Chemotaxis for human monocytes by fibrinogen-derived peptides. Br J Haematol 1976;32:507-514.
41. [41] Loscalzo J. The relationship between atherosclerosis and thrombosis. Circulation 1992;86(Suppl III):III-95-III-99.
42. [42] Smith EB, Keen GEA, Grant A, Stirk C. Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990;10:263-275.
43. [43] Muller DWM, Ellis SG, Topol EJ. Experimental models of coronary restenosis. J Am Coll Cardiol 1992;19:418-432.
44. [44] Karim MAK, Miller DD, Farrar MA, Elefteriades E, Reddy BH, Breland CM, Samarel AM. Histomorphometric and biochemical correlates of arterial procollagen gene expression during vascular repair after experimental angioplasty. Circulation 1995;91:2049-2057.
45. [45] Roubin GS, Cannon AD, Agrawal SK et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992;85:916-927.
46. [46] George BS, Voorhees III WD, Roubin GS et al. Multi-center investigators of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: clinical and angiographic outcome. J Am Coll Cardiol 1993;22:135-142.
47. [47] Colombo A, Hall P, Nakamura S et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:167-188.